Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of BPI-16350 plus fulvestrant versus placebo plus fulvestrant in HR-positive, HER2-negative advanced breast cancer after progression on endocrine therapy
CTR20221037Phase 3Active
- Sponsor
- Betta Pharmaceuticals
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing BPI-16350 + fulvestrant with Placebo + fulvestrant (2 arms). Primary endpoint: Progression-free survival by investigator assessment. Started Jun 2022; status: active.
02
Drugs
tibremciclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20221037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221037.